Linear mixed model results, fixed effects for time points, group, time points x group and univariate effects in the two groups WAD grades 2 and 3. by Anneli Peolsson (7867601)

Subjects:

Number of visits per clinic type, 2013-2015. by Jacob Dreiher (14856863)

“…During PE, statistically significant longer waiting times were found for surgery (+1.0 day) and imaging (+1.1 days), while a 2.4 days decrease was noted in pediatrics, controlled for age, sex, ethnicity and the daily number of visits. …”

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects:

Characteristics of patients who decreased their screen time by more than 60 minutes after the challenge. by Annaëlle Le Steunf (19838110)

Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

Subjects:

Infection of humanized mice resulted in decrease in pathogenicity in HTLV-1-CTCF infected mice. by Ancy Joseph (5634794)

iKIR score decreases protection associated with protective class II genotypes in T1D. by Laura Mora-Bitria (20477525)

Prenatal alcohol exposure (PAE) decreases brain and body weights at E14 and P0. by Danielle Sambo (6077924)

Weighted Linear Regression Analysis of BRI and ASM/BMI. by Wei Huang (36889)

Subjects:

Effects of GJE extract treatment decreased expression of NF-kB p65. by Natnicha Suttawong (22367172)

Forest plot of the second endpoint of the clinical symptom improvement. by Jin-Min Gu (17915039)

Subjects:

The reduced virulence of Δalta1 mutants is not primarily due to a decrease in growth. by Shuhuan Zhang (748003)

The ATR-CHK1 inhibitor AZD6738 decreases HBV cccDNA level. by Kaitao Zhao (3617825)

ROBINS-I assessments. by Martha R. Smith (20410184)

Subjects:

S8 File - by Martha R. Smith (20410184)

Subjects:

Study populations of included studies. by Martha R. Smith (20410184)

Subjects: